Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation - Takeaways - MDSpire

Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

  • By

  • Zineb Benbrahim

  • Oumaima Siyouri

  • Mohamed Fetohi

  • Nadia Benchakroun

  • Nabil Ismaili

  • Nssiba Bahra

  • Nabil Tachfouti

  • Brahim El Ghissassi

  • Fatima Zahra El M’Rabet

  • Rhizlane Belbaraka

  • Ali Tahri

  • Abdelkader Acharqi

  • Nawfel Mellas

  • January 26, 2026

  • 0 min

Share

  • 1

    Lung cancer is the leading cause of cancer death globally, with a 5-year survival rate of only 17.7% for patients.

  • 2

    Immune checkpoint inhibitors (ICIs) have improved overall survival rates in advanced lung cancer, becoming the standard of care.

  • 3

    In Morocco, 95.8% of lung cancer cases are diagnosed at advanced stages, highlighting the need for effective systemic therapies.

  • 4

    The study included 158 Moroccan patients treated with ICIs, with a median overall survival of 17 months.

  • 5

    The 12-month overall survival rate for all patients treated with ICIs in the study was 71.1%.

Original Source(s)

Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

  • by Zineb Benbrahim, Oumaima Siyouri, Mohamed Fetohi, Nadia Benchakroun, Nabil Ismaili, Nssiba Bahra, Nabil Tachfouti, Brahim El Ghissassi, Fatima Zahra El M’Rabet, Rhizlane Belbaraka, Ali Tahri, Abdelkader Acharqi, Nawfel Mellas

  • January 26, 2026

Related Content

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

Tumor immune microenvironment in non-small cell lung cancer progression

Non-invasive radiogenomic mapping of the SMARCAL1-driven ferroptotic niche is associated with longitudinal MRD-negative surveillance in early-stage NSCLC